Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease

• Autores: Eliot A. Brinton
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 45, Nº. 1, 2016 (Ejemplar dedicado a: Lipidology), págs. 185-204
• Idioma: inglés
• Enlaces
  • Texto Completo Ejemplar
• Resumen

  • Mendelian randomization data strongly suggest that hypertriglyceridemia (HTG) causes atherosclerotic cardiovascular disease (ASCVD), and so triglyceride (TG) level–lowering treatment in HTG is now more strongly recommended to address the residual ASCVD risk than has been the case in (generally earlier) published guidelines. Fibrates are the best-established agents for TG level lowering and are generally used as first-line treatment of TG levels greater than 500 mg/dL. Statins are the best-established agents for ASCVD prevention, and so are usually used as first-line treatment of TG levels less than 500 mg/dL.